Nailfold Capillary Blood Flow With Latanoprost Bunod
Study Details
Study Description
Brief Summary
The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Detailed Description
In this study, the study team investigates the effect of topically-applied latanoprostene bunod (LTB) on the blood flow at the nailfold of the 4th finger in patients with primary open angle glaucoma. LTB is a new anti-glaucoma eye drop which received FDA clearance in early November 2017. It has two components: the prostaglandin analog (PGA) which decreases intraocular pressure (IOP) by enhancing the drainage of the aqueous (the fluid in the front part of the eye) from the eye, and the nitric oxide (NO) moiety which naturally dilates arteries in the body. The capillaries at the nailfold are comparable to those of the optic nerve head, which makes them a reasonable surrogate for evaluation of the effect of LTB on the blood flow. Therefore, this study may provide indirect evidence for the beneficial effect of LTB on blood flow to optic nerve which can potentially save the optic nerve from glaucomatous damage. Primary open angle glaucoma is a progressive condition and is the most common cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is a subset of the glaucomas defined by an open, normal appearing anterior chamber angle and raised intraocular pressure (IOP), with no other underlying disease.
In addition to LTB, the study team will use latanoprost (L), an-FDA approved PGA anti-glaucoma eye drop and normal saline (NS: the physiologic solution composed of 0.9% salt and water), as controls to make sure the effects of LPB on nail fold capillary blood flow is not due to its PGA (as L is) or due to the placebo effect (as NS is).
This study may also serve as background information for the development of new anti-glaucoma medications which can be injected into the eye to facilitate blood flow to the optic nerve.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Latanoprost 0.005% Latanoprost 0.005% drops to the nailfold. |
Drug: Latanoprost 0.005%
Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Other Names:
Diagnostic Test: Nailfold capillaroscopy
An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Other Names:
|
Experimental: Latanoprost bunod 0.024% Latanoprost bunod 0.024% drops to the nailfold. |
Drug: Latanoprost bunod 0.024%
Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Other Names:
Diagnostic Test: Nailfold capillaroscopy
An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Other Names:
|
Placebo Comparator: Normal saline 0.9% Normal saline 0.9% to the nailfold. |
Drug: Normal saline 0.9%
Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Diagnostic Test: Nailfold capillaroscopy
An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- NFC Blood Flow at Baseline and 15 Minutes [baseline and 15 minutes]
NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
40 years old to 80 years old
-
All participants will have open angles and no signs of secondary glaucoma such as exfoliation syndrome
-
Untreated intraocular pressure (IOP) may be ≤ 21mmHg or ≥ 21mmHg in both eyes
-
The cup-to-disc ratio (CDR) ≥ 0.6 in both eyes and CDR asymmetry ≤ 0.2.
-
POAG patients will have reliable Humphrey Visual Field (HVF) loss consistent with optic nerve damage
-
POAG patients can have any stage of POAG and be on any form of treatment for their disease.
-
Willingness to sign informed consent and comply with study procedures.
Exclusion Criteria:
-
History of non-POAG forms of glaucoma
-
Pregnancy
-
Inability to give informed consent
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | New York Eye and Ear Infirmary of Mount Sinai | New York | New York | United States | 10003 |
Sponsors and Collaborators
- Icahn School of Medicine at Mount Sinai
Investigators
- Principal Investigator: Robert Ritch, MD, Icahn School of Medicine at Mount Sinai
Study Documents (Full-Text)
More Information
Publications
None provided.- GCO 18-2686
Study Results
Participant Flow
Recruitment Details | Recruitment occurred at New York Eye and Ear Infirmary of Mount Sinai |
---|---|
Pre-assignment Detail |
Arm/Group Title | Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% |
---|---|---|---|
Arm/Group Description | Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired. Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger. | Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. |
Period Title: Overall Study | |||
STARTED | 12 | 21 | 14 |
COMPLETED | 12 | 21 | 14 |
NOT COMPLETED | 0 | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% | Total |
---|---|---|---|---|
Arm/Group Description | Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired. Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger. | Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | Total of all reporting groups |
Overall Participants | 12 | 21 | 14 | 47 |
Age (years) [Mean (Standard Deviation) ] | ||||
Mean (Standard Deviation) [years] |
67.08
(5.95)
|
66.95
(8.86)
|
66.5
(8.50)
|
66.84
(7.77)
|
Sex: Female, Male (Count of Participants) | ||||
Female |
7
58.3%
|
14
66.7%
|
8
57.1%
|
29
61.7%
|
Male |
5
41.7%
|
7
33.3%
|
6
42.9%
|
18
38.3%
|
Ethnicity (NIH/OMB) (Count of Participants) | ||||
Hispanic or Latino |
3
25%
|
5
23.8%
|
3
21.4%
|
11
23.4%
|
Not Hispanic or Latino |
9
75%
|
16
76.2%
|
11
78.6%
|
36
76.6%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Race (NIH/OMB) (Count of Participants) | ||||
American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Asian |
1
8.3%
|
4
19%
|
2
14.3%
|
7
14.9%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Black or African American |
2
16.7%
|
2
9.5%
|
1
7.1%
|
5
10.6%
|
White |
9
75%
|
14
66.7%
|
10
71.4%
|
33
70.2%
|
More than one race |
0
0%
|
1
4.8%
|
1
7.1%
|
2
4.3%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Outcome Measures
Title | NFC Blood Flow at Baseline and 15 Minutes |
---|---|
Description | NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand. |
Time Frame | baseline and 15 minutes |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% |
---|---|---|---|
Arm/Group Description | Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired. Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger. | Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. |
Measure Participants | 12 | 21 | 14 |
Baseline |
72.52
(37.76)
|
83.94
(78.31)
|
93.01
(61.4)
|
15 minutes |
60.50
(42.81)
|
75.57
(44.68)
|
69.70
(41.46)
|
Adverse Events
Time Frame | 15 minutes | |||||
---|---|---|---|---|---|---|
Adverse Event Reporting Description | ||||||
Arm/Group Title | Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% | |||
Arm/Group Description | Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired. Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger. | Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy. | |||
All Cause Mortality |
||||||
Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/12 (0%) | 0/21 (0%) | 0/14 (0%) | |||
Serious Adverse Events |
||||||
Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/12 (0%) | 0/21 (0%) | 0/14 (0%) | |||
Other (Not Including Serious) Adverse Events |
||||||
Latanoprost 0.005% | Latanoprost Bunod 0.024% | Normal Saline 0.9% | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/12 (0%) | 0/21 (0%) | 0/14 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Harriet Lloyd |
---|---|
Organization | Icahn School of Medicine at Mount Sinai |
Phone | 212-979-4672 |
hlloyd@nyee.edu |
- GCO 18-2686